Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci.[L32965] Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class.[A233425] A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.
Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant _Enterococcus faecium_ infections.[L32965] Examples of susceptible bacteria include _Staphylococcus aureus_, _Streptococcus pneumoniae_, _Streptococcus pyogenes_, and _Streptococcus agalactiae_.[L32965] Linezolid is not indicated for the treatment of Gram-negative infections, nor has it been evaluated for use longer than 28 days.[L32965]
Categories
Acetamides
Acetates
Acids, Acyclic
Agents that produce hypertension
Agents that reduce seizure threshold
Amides
Anti-Bacterial Agents
Anti-Infective Agents
Antibacterials for Systemic Use
Antidepressive Agents
Antiinfectives for Systemic Use
Central Nervous System Depressants
Enzyme Inhibitors
Immunosuppressive Agents
Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
Monoamine Oxidase Inhibitors
Myelosuppressive Agents
OAT1/SLC22A6 inhibitors
OAT3/SLC22A8 Inhibitors
Oxazolidinone Antibacterial
Oxazolidinones
Protein Synthesis Inhibitors
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
